Aaa Usa Inc Company Profile

« Back to Dashboard

What is the competitive landscape for AAA USA INC

AAA USA INC has one approved drug.

There are nine US patents protecting AAA USA INC drugs.

Summary for Aaa Usa Inc

US Patents:	9
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Aaa Usa Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aaa Usa Inc	LUTATHERA	lutetium lu-177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018	AP	RX	Yes	Yes
Aaa Usa Inc	LUTATHERA	lutetium lu-177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018	AP	RX	Yes	Yes
Aaa Usa Inc	LUTATHERA	lutetium lu-177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018	AP	RX	Yes	Yes
Aaa Usa Inc	LUTATHERA	lutetium lu-177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018	AP	RX	Yes	Yes	12,168,063*PED				Y
Aaa Usa Inc	LUTATHERA	lutetium lu-177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018	AP	RX	Yes	Yes	12,415,003*PED				Y

International Patents for Aaa Usa Inc Drugs

Country	Patent Number	Estimated Expiration
Slovenia	4541381
Croatia	P20260338
Denmark	4541380
Finland	4541381
Japan	7796696

Supplementary Protection Certificates for Aaa Usa Inc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
4095130	202440024	Slovenia		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; NATIONAL AUTHORISATION NUMBER: EU/1/22/1703; DATE OF NATIONAL AUTHORISATION: 20221209; AUTHORITY FOR NATIONAL AUTHORISATION: EU
4095130	2490022-7	Sweden		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130	CA 2024 00027	Denmark		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDETETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130	2024C/528	Belgium		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; AUTHORISATION NUMBER AND DATE: EU/1/22/1703 20221212
4095130	301281	Netherlands		PRODUCT NAME: LUTETIUM (177-LU)-VIPIVOTIDE TETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703, 20221212

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Aaa Usa Inc

Pharmaceutical Competitive Landscape Analysis: Aaa USA Inc Market Position, Strengths, and Strategic Insights

Last updated: July 24, 2026

Aaa USA Inc’s competitive position can’t be assessed because there is no identifiable drug portfolio, marketed products, active ingredients, FDA registrations, or patent estate to analyze. Without a specific, verifiable product set tied to Aaa USA Inc (e.g., NDC-linked brands, labeled indications, and the company’s US legal entity ownership), any market positioning, IP strength, litigation risk, or generic/biosimilar launch exposure would be fabricated.

What products does Aaa USA Inc market in the US?

No analyzable data.

Which active ingredients and dosage forms are in Aaa USA Inc’s US portfolio?

No analyzable data.

What FDA approval letters or supplements are linked to Aaa USA Inc?

No analyzable data.

How strong is Aaa USA Inc’s patent estate in the US?

No analyzable data.

What patents protect Aaa USA Inc products (composition, formulation, method-of-use)?

No analyzable data.

When do Aaa USA Inc patents expire and when does exclusivity end?

No analyzable data.

What is the Orange Book status of Aaa USA Inc drugs?

No analyzable data.

Which Aaa USA Inc products have listed patents and FDA regulatory exclusivities?

No analyzable data.

Which patents are most likely to be asserted in litigation?

No analyzable data.

How many Paragraph IV challenges exist against Aaa USA Inc products?

No analyzable data.

Which ANDA filers are challenging Aaa USA Inc’s listed patents?

No analyzable data.

What settlement agreements or consent judgments affect Aaa USA Inc exclusivity?

No analyzable data.

What patent litigation affects Aaa USA Inc in the US?

No analyzable data.

Which courts handle Aaa USA Inc cases and what claims were asserted?

No analyzable data.

What is the current procedural posture of Aaa USA Inc disputes?

No analyzable data.

What generic entry risks exist for Aaa USA Inc products?

No analyzable data.

What is the earliest feasible generic or 505(b)(2) entry date?

No analyzable data.

Which manufacturing/IP barriers block generic substitution?

No analyzable data.

How does Aaa USA Inc compare with competitors on product breadth and IP density?

No analyzable data.

Which peer companies sell competing products for the same indications?

No analyzable data.

How does Aaa USA Inc’s portfolio map against likely generic/biosimilar targets?

No analyzable data.

What biologics or biosimilar risks apply to Aaa USA Inc?

No analyzable data.

What BLA/BSUFA pathway items would matter?

No analyzable data.

Which biosimilar filings could trigger litigation windows?

No analyzable data.

What formulations are protected by Aaa USA Inc (if any)?

No analyzable data.

Are there barriers around extended-release, abuse-deterrent, or specialty delivery systems?

No analyzable data.

What licensing deals or partner arrangements impact Aaa USA Inc’s competitive position?

No analyzable data.

Which companies have co-promotion, distribution, or commercialization agreements?

No analyzable data.

What IP is licensed in or out (brands, process, know-how)?

No analyzable data.

Key Takeaways

No analyzable content for Aaa USA Inc without an identified, source-verifiable US product and IP footprint.

FAQs

1. What NDCs and brands are associated with Aaa USA Inc in FDA datasets?
2. Which Aaa USA Inc drugs have Orange Book patents listed for each dosage strength?
3. What are the next milestone dates for ANDA submissions challenging Aaa USA Inc patents?
4. Which jurisdictions outside the US affect Aaa USA Inc IP enforcement strategy?
5. Does Aaa USA Inc compete mainly through brand value, distribution, or manufacturing exclusivity?

References (APA)

No citations provided because no verifiable sources were supplied in the request.